Marcelo H Petri1, Andrés Laguna-Fernandez1, Hildur Arnardottir1, Craig E Wheelock2, Mauro Perretti3, Göran K Hansson1, Magnus Bäck1,4. 1. Experimental Cardiovascular Research Group, Cardiovascular Medicine Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. 2. Department of Medical Biochemistry and Biophysics, Karlinska Institutet, Stockholm, Sweden. 3. William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK. 4. Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
Abstract
BACKGROUND AND PURPOSE: Atherosclerosis is characterized by a chronic non-resolving inflammation in the arterial wall. Aspirin-triggered lipoxin A4 (ATL) is a potent anti-inflammatory mediator, involved in the resolution of inflammation. However, the therapeutic potential of immune targeting by means of ATL in atherosclerosis has not previously been explored. The aim of the present study was to determine the effects of ATL and its receptor Fpr2 on atherosclerosis development and progression in apolipoprotein E deficient (ApoE-/- ) mice. EXPERIMENTAL APPROACH: ApoE-/- × Fpr2+/+ and ApoE-/- × Fpr2-/- mice were generated. Four-week-old mice fed a high-fat diet for 4 weeks and 16-week-old mice fed chow diet received osmotic pumps containing either vehicle or ATL for 4 weeks. Atherosclerotic lesion size and cellular composition were measured in the aortic root and thoracic aorta. Lipid levels and leukocyte counts were measured in blood and mRNA was isolated from abdominal aorta and spleen. KEY RESULTS: ATL blocked atherosclerosis progression in the aortic root and thoracic aorta of ApoE-/- mice. In addition, ATL reduced macrophage infiltration and apoptotic cells in atherosclerotic lesions. The mRNA levels of several cytokines and chemokines in the spleen and aorta were reduced by ATL, whereas circulating leukocyte levels were unchanged. The ATL-induced athero-protection was absent in ApoE-/- mice lacking the Fpr2 receptor. CONCLUSION AND IMPLICATIONS: ATL blocked atherosclerosis progression by means of an Fpr2-mediated reduced local and systemic inflammation. These results suggest this anti-inflammatory and pro-resolving agent has therapeutic potential for the treatment of atherosclerosis. LINKED ARTICLES: This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc.
BACKGROUND AND PURPOSE: Atherosclerosis is characterized by a chronic non-resolving inflammation in the arterial wall. Aspirin-triggered lipoxin A4 (ATL) is a potent anti-inflammatory mediator, involved in the resolution of inflammation. However, the therapeutic potential of immune targeting by means of ATL in atherosclerosis has not previously been explored. The aim of the present study was to determine the effects of ATL and its receptor Fpr2 on atherosclerosis development and progression in apolipoprotein E deficient (ApoE-/- ) mice. EXPERIMENTAL APPROACH: ApoE-/- × Fpr2+/+ and ApoE-/- × Fpr2-/- mice were generated. Four-week-old mice fed a high-fat diet for 4 weeks and 16-week-old mice fed chow diet received osmotic pumps containing either vehicle or ATL for 4 weeks. Atherosclerotic lesion size and cellular composition were measured in the aortic root and thoracic aorta. Lipid levels and leukocyte counts were measured in blood and mRNA was isolated from abdominal aorta and spleen. KEY RESULTS: ATL blocked atherosclerosis progression in the aortic root and thoracic aorta of ApoE-/- mice. In addition, ATL reduced macrophage infiltration and apoptotic cells in atherosclerotic lesions. The mRNA levels of several cytokines and chemokines in the spleen and aorta were reduced by ATL, whereas circulating leukocyte levels were unchanged. The ATL-induced athero-protection was absent in ApoE-/- mice lacking the Fpr2 receptor. CONCLUSION AND IMPLICATIONS: ATL blocked atherosclerosis progression by means of an Fpr2-mediated reduced local and systemic inflammation. These results suggest this anti-inflammatory and pro-resolving agent has therapeutic potential for the treatment of atherosclerosis. LINKED ARTICLES: This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc.
Authors: Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath Journal: Br J Pharmacol Date: 2015-07 Impact factor: 8.739
Authors: Shantel A Vital; Felix Becker; Paul M Holloway; Janice Russell; Mauro Perretti; D Neil Granger; Felicity N E Gavins Journal: Circulation Date: 2016-05-06 Impact factor: 29.690
Authors: Karen J Ho; Matthew Spite; Christopher D Owens; Hope Lancero; Alex H K Kroemer; Reena Pande; Mark A Creager; Charles N Serhan; Michael S Conte Journal: Am J Pathol Date: 2010-08-13 Impact factor: 4.307
Authors: Françoise Stanke-Labesque; Jean-Louis Pépin; Tiphaine de Jouvencel; Claire Arnaud; Jean-Philippe Baguet; Marcelo H Petri; Renaud Tamisier; Jean François Jourdil; Patrick Lévy; Magnus Bäck Journal: J Lipid Res Date: 2012-07-03 Impact factor: 5.922
Authors: Cindy Barnig; Manuela Cernadas; Stefanie Dutile; Xiaoli Liu; Mark A Perrella; Shamsah Kazani; Michael E Wechsler; Elliot Israel; Bruce D Levy Journal: Sci Transl Med Date: 2013-02-27 Impact factor: 17.956
Authors: Janine M van Gils; Merran C Derby; Luciana R Fernandes; Bhama Ramkhelawon; Tathagat D Ray; Katey J Rayner; Sajesh Parathath; Emilie Distel; Jessica L Feig; Jacqueline I Alvarez-Leite; Alistair J Rayner; Thomas O McDonald; Kevin D O'Brien; Lynda M Stuart; Edward A Fisher; Adam Lacy-Hulbert; Kathryn J Moore Journal: Nat Immunol Date: 2012-01-08 Impact factor: 25.606
Authors: Marcelo H Petri; Andrés Laguna-Fernández; Maria Gonzalez-Diez; Gabrielle Paulsson-Berne; Göran K Hansson; Magnus Bäck Journal: Cardiovasc Res Date: 2014-10-23 Impact factor: 10.787